AEON Biopharma, Inc. | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.39.

EBIT: As of FY2025 Q3, the actual value is USD -2.493 M.

Segment Revenue

• AEON Biopharma, Inc. did not report any revenue from product sales for the periods ended September 30, 2025, and 2024, as the company has not yet commercialized its product candidates.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $4.5 million, compared to a net loss of $6.2 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $2.1 million, compared to a net income of $39.9 million for the same period in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $2.5 million, a decrease from $4.0 million in the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $7.3 million, compared to - $75.3 million in 2024, primarily due to changes in fair value of contingent consideration.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities for the nine months ended September 30, 2025, was $12.6 million, compared to $19.7 million for the same period in 2024.
• Free Cash Flow: Not explicitly reported, but the net increase in cash for the nine months ended September 30, 2025, was $5.9 million, compared to a decrease of $4.6 million in 2024.

Unique Metrics

• Convertible Notes: The fair value of convertible notes as of September 30, 2025, was $17.1 million, compared to $11.7 million as of December 31, 2024.
• Warrant Liabilities: The fair value of warrant liabilities as of September 30, 2025, was $2.3 million, compared to $1.2 million as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: AEON Biopharma, Inc. plans to develop and seek regulatory approval of ABP-450 as a biosimilar product in the U.S. through a Biologics License Application under Section 351(k), using AbbVie Inc.’s product Botox as a proposed reference product. The company aims to address the global therapeutic botulinum toxin market, estimated at $3.3 billion.
• Non-Core Business: The company announced a strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for ABP-450, discontinuing its Phase 2 clinical trials for episodic and chronic migraine to implement cash preservation measures.
• Priority: The company is focused on securing additional capital to fund its operations and further develop ABP-450, with an emphasis on achieving regulatory approval and commercialization.